reSET can help patients stay on their recovery journey1-2*

For individuals with substance use disorder (SUD), reSET® is the first FDA-authorized prescription digital therapeutic that’s proven to increase abstinence and treatment retention. Patients download the reSET app to their smartphone for secure, discreet, convenient access to therapy, interactive learning, and support.

*During 12 weeks of treatment.

THE APP

reSET preview

Get a closer look at some of the treatment highlights.

reSET Product Video

Learn more about how reSET can complement and support existing treatment.

reSET product overview video thumbnail

THE PROOF

Results of a 12-week reSET study1-2

>2x

ABSTINENCE

In an analysis of patients whose primary substance of abuse was not opioids, adding reSET to outpatient treatment as usual (TAU) more than doubled abstinence rates during the last 4 weeks of the 12-week trial:


bar chart: reSET abstinence rate by treatment group

P=.0004

21%

RETENTION

In a secondary analysis of patients whose primary substance of abuse was not opioids, adding reSET to outpatient TAU significantly improved retention rates by 21% compared to TAU alone during the last 4 weeks of the 12-week trial§:


bar chart: reSET-O retention rate by treatment group

P=.0042

Treatment with reSET did not demonstrate a significant difference in unanticipated adverse events compared with TAU.2

rTAU: reduced treatment as usual in which 2 hours of face-to-face therapy each week was replaced with use of the desktop-based Therapeutic Education System, which has equivalent content to reSET.

§Retention rate: Relative change defined as (76.2-63.2)/63.2 = 21% (reSET).

CASE STUDIES

Real experiences,
real results

reSET and reSET-O case studies

CASE STUDIES

Real experiences,
real results

reSET and reSET-O® are helping practices
and their patients.

YOUR DASHBOARD

Clinician dashboard

Receive deeper insights into your patients’ progress.

reSET® Indications for Use:

reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.

It is intended to:

  • Increase abstinence from a patient’s substances of abuse during treatment, and
  • Increase retention in the outpatient treatment program.

reSET® Important Safety Information for Clinicians:

Warnings: reSET is intended for patients whose primary language is English or Spanish with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner and is not intended to reduce the amount of face-to-face clinician time. reSET does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with substance use disorder also have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should engage in their normal care practices to monitor patients for medical problems and mental health disorders, including risk for harming others and/or themselves.

The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.

The effectiveness of reSET has not been demonstrated in patients currently reporting opioids as their primary substance of abuse.

Please see the Clinician Brief Summary Instructions for reSET.

reSET-O® Indications for Use:

reSET-O prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

reSET-O® Important Safety Information for Clinicians:

Warnings/precautions: reSET-O is intended for patients whose primary language is English or Spanish with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.

The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

Please see the Clinician Brief Summary Instructions for reSET-O.